Evidence map›Paper›PMID 36382536›Full record

ArticleAnnals of the New York Academy of Sciences2023

Antibodies as drugs-a Keystone Symposia report.

Jennifer Cable, Erica Ollmann Saphire, Adrian C Hayday, Timothy D Wiltshire, Jarrod J Mousa, David P Humphreys, Esther C W Breij, Pierre Bruhns, Matteo Broketa, Genta Furuya and 21 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of the New York Academy of Sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Jennifer CablePhD Science Writer, New York, New York, USA.
Erica Ollmann SaphireCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California, USA.
Adrian C HaydayPeter Gorer Department of Immunobiology, King's College London, London, UK.
Timothy D WiltshireMayo Clinic, Rochester, Minnesota, USA.
Jarrod J MousaDepartment of Infectious Diseases and Center for Vaccines and Immunology, College of Veterinary Medicine, Athens, Georgia, USA.
David P HumphreysProtein Sciences, UCB Pharma, Berkshire, UK.
Esther C W BreijTranslational Research and Precision Medicine, Genmab BV, Utrecht, the Netherlands.
Pierre BruhnsInstitut Pasteur, Université de Paris, Unit of Antibodies in Therapy and Pathology, Paris, France.
Matteo BroketaInstitut Pasteur, Université de Paris, Unit of Antibodies in Therapy and Pathology, Paris, France.
Genta FuruyaDepartment of Preventive Medicine and Department of Pathology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
Blake M HauserRagon Institute of MGH, MIT, and Harvard, Cambridge, Massachusetts, USA.
Matthieu MahévasService de Médecine Interne, Centre de Référence des Cytopénies Auto-immunes de l'adulte, Centre Hospitalier Universitaire Henri-Mondor, Assistance Publique-Hôpitaux de Paris, Université Paris-Est Créteil, Créteil, France.
Andrea CarfiModerna Inc., Cambridge, Massachusetts, USA.
Tineke CantaertImmunology Unit, Institut Pasteur du Cambodge, The Pasteur Network, Phnom Penh, Cambodia.
Peter D KwongVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Prabhanshu TripathiVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Jonathan H DavisInvenra, Inc, Madison, Wisconsin, USA.
Neil BrewisF-star Therapeutics Ltd., Cambridge, UK.
Bruce A KeytIGM Biosciences, Inc., Mountainview, California, USA.
Felix L FennemannLava Therapeutics, Utrecht, the Netherlands.
Vincent DussuptEmerging Infectious Diseases Branch, U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
Arvind SivasubramanianComputational Biology, Adimab, Palo Alto, California, USA.
Philip M KimDepartment of Molecular Genetics, Donnelly Centre for Cellular and Biomolecular Research, Toronto, Ontario, Canada.
Reda RawiVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Eve RichardsonDepartment of Statistics, University of Oxford, Oxford, UK.
Daniel LeventhalGenerate Biomedicines, Somerville, Massachusetts, USA.
Rachael M WoltersDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Cecile A W GeuijenMerus N.V., Utrecht, the Netherlands.
Matthew A SleemanRegeneron Pharmaceuticals, Tarrytown, New York, USA.
Niccolo PengoMabylon AG, Schlieren, Switzerland.
Francesca Rose DonnellanUniversity of Oxford, Oxford, UK.

Funding

Neutralization Mechanisms Of Anti-HIV-1 Monoclonal AntibodiesZIAAI005022 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI ZHOU, TONGQING · 2009 to 2025
$24.6M
MOLECULAR BIOPHYSICS TRAINING PROGRAM AT VANDERBILTT32GM008320 · NIGMS · VANDERBILT UNIVERSITY · PI CHAZIN, WALTER J. · 1989 to 2023
$7.9M
Inter-regional study of transmission, adaptation and pathogenesis of viruses with pandemic potential in Southeast Asia and West/Central AfricaU01AI151758 · NIAID · INSTITUT PASTEUR · PI SAKUNTABHAI, ANAVAJ, SIMON-LORIERE, ETIENNE · 2020 to 2024
$6.7M
Computational Algorithms, Methods, and Tools for Antibody DesignZICAI005140 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI RAWI, REDA · 2020 to 2025
$3.4M
Structural and mechanistic insights into antibody neutralization of human metapneumovirusR01AI143865 · NIAID · UNIVERSITY OF GEORGIA · PI MOUSA, JARROD · 2019 to 2023
$3.0M
Howard Hughes Medical InstituteNIAID NIH HHS R01 AI143865NIAID NIH HHS U01 AI151758NIGMS NIH HHS T32 GM008320Wellcome Trust 208710/Z/17/Z
6 · The paper itself

Abstract

Therapeutic antibodies have broad indications across diverse disease states, such as oncology, autoimmune diseases, and infectious diseases. New research continues to identify antibodies with therapeutic potential as well as methods to improve upon endogenous antibodies and to design antibodies de novo. On April 27-30, 2022, experts in antibody research across academia and industry met for the Keystone symposium "Antibodies as Drugs" to present the state-of-the-art in antibody therapeutics, repertoires and deep learning, bispecific antibodies, and engineering.

Indexed as

Antibodies, BispecificHumansImmunotherapyAntibodies, Bispecificallergiesantibodiesantibody designbispecific antibodiesSARS-CoV-2therapeutic antibodies

Identifiers

PMID36382536
PMCPMC10103175

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.